Skip to main content

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Active, not recruiting · NCT06693531

Conditions: Eosinophilic Esophagitis (EoE)

At a glance

Research payments reported, 2025
$1.7M
U.S. investigators named
43
Sites paid
34
Planned or actual enrollment
368

About the trial

Sponsor
Regeneron Pharmaceuticals (with Sanofi)
Tested
dupilumab (drug)
Dates
Started 2024-11-22; completion 2030-05-22
Results posted
Not yet

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms h…

From ClinicalTrials.gov, last updated 2026-08-12. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $1.7M in research payments for this study in 2025 (329 payments).

Products named: Dupixent

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.